Brief: A1M Pharma: ROSGard shows strong protective effect against renal damage in connection with radiation therapy in preclinical long-term study

Disruptive Pharma AB (publ)

29/03/2017 13:40

March 29 (Reuters) - A1M PHARMA AB  A1M.ST : 
    * PRELIMINARY DATA FROM THE COMPLETED PRECLINICAL LONG-TERM 
STUDY WITH AN ANIMAL MODEL CLEARLY ESTABLISH THE STRONG 
PROTECTIVE EFFECT AGAINST RENAL DAMAGE OF THE ACTIVE SUBSTANCE 
IN THE CANDIDATE DRUG ROSGARD IN CONNECTION WITH RADIATION 
THERAPY 
    * CLINICAL STUDIES ARE SCHEDULED TO START IN THE BEGINNING 
OF 2018 
 
     
 Source text: http://bit.ly/2mPzCgw 
     
 Further company coverage:  A1M.ST   
    
 
 
 (Gdynia Newsroom) 
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))